Published online before print October 27, 2008, doi: 10.1161/CIRCULATIONAHA.107.750000
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:2029-2037.)
© 2008 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
From the Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (S.J.C., J.P., J.E., J.S.H., S.Y.); University of Missouri, Columbia (G.F.); Cardiac Clinic, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa (P.C.); and Department of Cardiovascular Research, Istituto Mario Negri, Milano, Italy (M.G.F.).
Correspondence to Dr Stuart Connolly, 237 Barton St E, Suite 504, Hamilton, Ontario, L8L 2X2 Canada. E-mail connostu{at}phri.ca
Received November 6, 2007; accepted August 27, 2008.
Background— Oral anticoagulation (OAC) therapy is effective in atrial fibrillation but requires vigilance to maintain the international normalized ratio in the therapeutic range. This report examines how differences in time in therapeutic range (TTR) between centers and between countries affect the outcomes of OAC therapy.
Methods and Results— In a posthoc analysis, the TTRs of patients on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE W]) were used to calculate the mean TTR for each of 526 centers and 15 countries. Proportional-hazards analysis, with and without adjustment for baseline variables, was performed, with patients stratified by TTR quartile and country. A wide variation in TTRs was found between centers, with mean TTRs for centers in the 4 quartiles of 44%, 60%, 69%, and 78%. For patients at centers below the median TTR (65%), no treatment benefit was demonstrated as measured by relative risk for vascular events of clopidogrel plus aspirin versus OAC (relative risk, 0.93; 95% confidence interval, 0.70 to 1.24; P=0.61). However, for patients at centers with a TTR above the study median, OAC had a marked benefit, reducing vascular events by >2-fold (relative risk, 2.14; 95% confidence interval, 1.61 to 2.85; P<0.0001). Mean TTR also varied between countries from 46% to 78%; relative risk (clopidogrel plus aspirin versus OAC) varied from 0.6 to 3.6 (a 5-fold difference). A population-average model predicted that a TTR of 58% would be needed to be confident that patients would benefit from being on OAC.
Conclusions— A wide variation exists in international normalized ratio control, as measured by TTR, between clinical centers and between countries, which has a major impact on the treatment benefit of OAC therapy. For centers and countries, a target threshold TTR exists (estimated between 58% and 65%) below which there appears to be little benefit of OAC over antiplatelet therapy.
CLINICAL PERSPECTIVE
Related Article:
-
Clinical Summaries
Circulation 2008 118: 2013-2014.[Extract] [Full Text]
This article has been cited by other articles:
 |
|
 |
|
  G. Y. H. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. G. M. Crijns Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation Chest, February 1, 2010; 137(2): 263 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Houston, R. Zarychanski, H. Tomoda, M. Moia, P. M. Mannucci, J. M. Worthington, M. Gattellari, L. Poller, J. Jespersen, S. Ibrahim, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., December 31, 2009; 361(27): 2671 - 2672. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF' Eur. Heart J., December 2, 2009; 30(24): 2969 - 2980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y.H. Lip, L. H. Rasmussen, S. B. Olsson, E. C. Jensen, A. L. Persson, U. Eriksson, K. F.C. Wahlander, and on behalf of the Steering Committee Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists Eur. Heart J., December 1, 2009; 30(23): 2897 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel and F. C. Tanner Direct thrombin inhibitors in atrial fibrillation reloaded Eur. Heart J., December 1, 2009; 30(23): 2832 - 2834. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Singer, M. C. Fang, and A. S. Go The International Normalized Ratio Range of 2.0 to 3.0 Remains Appropriate for Atrial Fibrillation Arch Intern Med, November 23, 2009; 169(21): 2032 - 2032. [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Holmes Jr and R. S. Schwartz Left Atrial Appendage Occlusion Eliminates the Need for Warfarin Circulation, November 10, 2009; 120(19): 1919 - 1926. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, H. J.G.M. Crijns, C. Torp-Pedersen, M. van Eickels, C. Gaudin, R. L. Page, S. H. Hohnloser, and for the ATHENA Investigators Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter Circulation, September 29, 2009; 120(13): 1174 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Ellis, M. H. Usman, P. G. Milner, D. M. Canafax, and M. D. Ezekowitz The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation Circulation, September 22, 2009; 120(12): 1029 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Gage Can We Rely on RE-LY? N. Engl. J. Med., September 17, 2009; 361(12): 1200 - 1202. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. A. Reilly, E. Themeles, J. Varrone, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation N. Engl. J. Med., September 17, 2009; 361(12): 1139 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Ann Intern Med, September 1, 2009; 151(5): 297 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart and J. L. Halperin Do Current Guidelines Result in Overuse of Warfarin Anticoagulation in Patients With Atrial Fibrillation? Ann Intern Med, September 1, 2009; 151(5): 355 - 356. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Singer, Y. Chang, M. C. Fang, L. H. Borowsky, N. K. Pomernacki, N. Udaltsova, and A. S. Go Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study Circ Cardiovasc Qual Outcomes, July 1, 2009; 2(4): 297 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ahmed, H. J. G. M. Crijns, and I. C. Van Gelder Treatment With Amiodarone to Prevent Atrial Fibrillation--Reply JAMA, March 11, 2009; 301(10): 1020 - 1020. [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Tay, D. A. Lane, and G. Y. H. Lip Challenges facing anticoagulation among the elderly and frail Age Ageing, March 1, 2009; 38(2): 140 - 142. [Full Text] [PDF]
|
|